產品描述: FRAX-1036是一種有效的、選擇性PAK抑制劑, 其對PAK1和PAK2的Ki值分別為23.3 nM和72.3 nM |
靶點:
PAK1(Cell-free assay):23.3 nM(Ki); PAK2(Cell-free assay):72.4 nM(Ki); PAK4(Cell-free assay):2.4 μM(Ki);PAK |
體外研究:
在PAK1擴增的MDA-MB-175種,2.5-5 μM FRAX1036的處理下,對1型PAK底物的磷酸化有抑制效果。用FRAX1035處理PAK1增殖的乳腺癌細胞能誘導凋亡。用FRAX103處理OVCAR-3細胞導致p53和p21的上調、cyclinc B1 的下調 |
體內研究:
在小鼠中,處理以FRAX1-26導致KT21腫瘤生長變慢。FRAX1-26很難通過血腦屏障 |
細胞實驗:
Cell lines: MDA-MB175細胞 Concentrations: 0, 0.5, 1, 2.5, 5 μM Incubation Time: 24 h Method: 將MDA-MB175細胞用不同濃度的FRAX1036處理24小時,然后用生物標記抗體對細胞裂解物進行免疫沉淀分析 |
動物實驗:
Animal Models: Pak2-deficient小鼠 Dosages: 30 mg/kg Administration: 口服 |
參考文獻:
1. Ong CC, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res. 2015, 17:59. 2. Kosoff RE, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Blood. 2015, 125(19):2995-3005. 3. Alexander B. Koval, et al. An optimized synthesis of the potent and selective Pak1 inhibitor FRAX-1036. Tetrahedron Letters. 2016, 57(3):449-451. 4. Chow HY, et al. Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 2015, 6(4): 1981-1994. |
溶解性:
soluble in 4-Methylpyridine |
保存條件:
-20℃ |
配置溶液濃度參考:
|
1mg |
5mg |
10mg |
1 mM |
1.93 ml |
9.652 ml |
19.303 ml |
5 mM |
0.386 ml |
1.93 ml |
3.861 ml |
10 mM |
0.193 ml |
0.965 ml |
1.93 ml |
50 mM |
0.039 ml |
0.193 ml |
0.386 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |